37th week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140255361 | ESTROGEN-RECEPTOR BASED LIGAND SYSTEM FOR REGULATING PROTEIN STABILITY - Disclosed herein are systems, methods and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand. | 2014-09-11 |
20140255362 | SRPX FOR TREATMENT OF CANCER - Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX. | 2014-09-11 |
20140255363 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS - The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma. | 2014-09-11 |
20140255364 | 3D CULTURE SYSTEM FOR CULTURING CELLS IN SYNOVIAL FLUID, CELLS CULTURED IN SYNOVIAL FLUID AND THEIR USE - Disclosed herein are materials and methods for culturing cells derived from joint cavities, said culturing being performed in the presence of synovial fluid. Also disclosed herein are cells cultured by the methods described herein, and their use for therapeutic purposes and for identifying therapeutic agents. | 2014-09-11 |
20140255365 | Oral Electrolyte Solution Containing Lactoferrin and Uses Thereof - The present disclosure relates to an oral electrolyte solution comprising lactoferrin. Lactoferrin may promote intestinal healing during a bout of diarrhea in a pediatric subject, thereby reducing the duration of diarrhea symptoms. Additionally, the oral electrolyte solutions disclosed herein may comprise | 2014-09-11 |
20140255366 | NOVEL COMPOSITIONS - The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 10 | 2014-09-11 |
20140255367 | Sweetening and Healthy Compositions and Methods Associated Therewith - Formulations are disclosed that contain one or more prebiotics and one or more probiotics. The formulations of the present invention may be used as a supplement that is also a sweetener. The supplement may be useful for anti-aging and/or anti-oxidant properties, increasing mental faculties and/or a decreasing cognitive decline, antibacterial properties, cardiovascular health properties, digestive health benefits such as being effective against irritable bowel syndrome, cognitive health benefits, mental health benefits, anti-inflammatory activity, dry skin treatment, and other benefits. | 2014-09-11 |
20140255368 | METHOD OF GENERATING TUMOR-SPECIFIC T CELLS - A method for the expansion of tumor-specific T-cells includes obtaining an enriched population of T-cells from a subject with cancer; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, to activate and expand the T-cells. | 2014-09-11 |
20140255369 | PRODUCTION AND USE OF RED BLOOD CELLS - The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation. | 2014-09-11 |
20140255370 | Dietary Supplement Composition - A dietary supplement composition is presented, which includes omega-3 fatty acids, one or more of tocopherols and tocotrienols, and/or one or more essential oils. The dietary supplement may provide numerous health benefits to the user, including improvements in cardiovascular health, ocular health, cerebral and cognitive function, muscle function, and athletic performance. This supplement also has pronounced anti-inflammatory benefits. The collective effect of the composition may also maximize the positive effects of omega-3 fatty acids while also reducing or eliminating any negative effects associated with these fats. | 2014-09-11 |
20140255371 | Physical Optimization Beverage - The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The compositions and methods described herein are useful for optimizing health and performance; preventing illness; decreasing recovery times from exertion, illness, and injury; increasing energy levels; improving exercise performance; improving hydration; preventing muscle damage after exercise; and increasing stamina during exercise. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production. | 2014-09-11 |
20140255372 | CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 2014-09-11 |
20140255373 | ALPHA-ALKOXYSILANE-TERMINATED PREPOLYMER FOR FAST-CURING SPRAY FOAMS WITH IMPROVED PROPELLANT GAS SOLUBILITY - The present invention relates to an alpha-alkoxysilane-terminated prepolymer preparable by reaction of at least one polyether polyol, of a polyisocyanate and of an alpha-alkoxysilane having at least one isocyanate-reactive group, said polyether polyol having a weight average of 500 to 7000 g/mol and having ethylene oxide and propylene oxide units, the proportion of ethylene oxide units being up to 50% by weight based on the polyether polyol. The invention further provides a process for preparing an inventive alpha-alkoxysilane-terminated prepolymer, a composition, a multicomponent system and a spray can comprising an inventive alpha-alkoxysilane-terminated prepolymer, and also a moulding obtainable by polymerization from an inventive alpha-alkoxysilane-terminated prepolymer. | 2014-09-11 |
20140255374 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 2014-09-11 |
20140255375 | THROMBOPOIETIC ACTIVITY OF TYROSYL-TRNA SYNTHETASE POLYPEPTIDES - Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia. | 2014-09-11 |
20140255376 | Regulation of Specific Spinal Neurons Regulating Pain Transmission - A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed. | 2014-09-11 |
20140255377 | PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-BINDING ARGININE DEIMINASE FOR CANCER TARGETING TREATMENT - The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. | 2014-09-11 |
20140255378 | PEGYLATED TYROSYL-TRNA SYNTHETASE POLYPEPTIDES - The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides. | 2014-09-11 |
20140255379 | STABILIZED COMPOSITIONS AGAINST IONISING RADIATION - This invention relates to improvements to medical devices such as biosensors containing proteins such as oxidoreductases, for example oxidase and/or peroxidase enzymes. More generally it relates to novel compositions containing proteins which are stabilised to ionising radiation. | 2014-09-11 |
20140255380 | METHODS OF ADMINISTERING 3, 4-DIAMINOPYRIDINE - Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases. | 2014-09-11 |
20140255381 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | 2014-09-11 |
20140255382 | SOLID COMPOSITION CONTAINING A HYPOTHIOCYANITE SALT - The present invention relates to a solid composition including at least one hypothiocyanite (OSCN | 2014-09-11 |
20140255383 | RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF - The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases. | 2014-09-11 |
20140255384 | METHODS OF TREATING AND PREVENTING SOCIAL COMMUNICATION DISORDER IN PATIENTS BY INTRANASAL ADMINISTRATION OF INSULIN - Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and/or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and/or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism. | 2014-09-11 |
20140255385 | TREATMENT OF GLIOBLASTOMA WITH PRODUCTS OBTAINED FROM CULTIVATION OF CORDYCEPS MILITARIS - Disclosed herein is that an active ingredient obtained from cultivation of | 2014-09-11 |
20140255386 | MICRORNA MODULATORS AND METHOD FOR IDENTIFYING AND USING THE SAME - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 2014-09-11 |
20140255387 | Genetic Alterations and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes - Compositions and methods for the diagnosis and treatment of T1D are disclosed. More specifically, the invention provides gene targets containing single nucleotide polymorphisms associated with this disease. Methods and kits for using the sequences so identified for diagnostic and therapeutic purposes are also provided. | 2014-09-11 |
20140255388 | TOLL LIKE RECEPTOR 3 ANTAGONISTS, METHODS AND USES - Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments, and methods of making and using the foregoing are disclosed. | 2014-09-11 |
20140255389 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development. | 2014-09-11 |
20140255390 | Method of Treating Rheumatoid Arthritis With An Anti-IL-6R Antibody - The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof. | 2014-09-11 |
20140255391 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2014-09-11 |
20140255392 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF - The present invention relates to substituted imidazopyridine compounds of general formula (I) in which R | 2014-09-11 |
20140255393 | COMPOSITIONS AND METHODS FOR AUTOIMMUNE DISEASE - Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (SCNP), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease. | 2014-09-11 |
20140255394 | Method of Treating Colorectal Cancer - The present invention relates to the use of certain platinum compounds including [PtCl | 2014-09-11 |
20140255395 | COMPLEMENT INHIBITION FOR IMPROVED NERVE REGENERATION - The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system. | 2014-09-11 |
20140255396 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2014-09-11 |
20140255397 | METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER - Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist. | 2014-09-11 |
20140255398 | ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN - The present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced. Furthermore, the present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced, and also the antigen-binding molecule has cytotoxicity or antiproliferative action against cancer cells, foreign biological species, or such that express the antigen to which the antigen-binding molecule binds. | 2014-09-11 |
20140255399 | SEPARATION METHOD FOR FUCOSYLATED ANTIBODIES - The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to Fc receptors. The invention further relates to the use of Fc receptors for the separation of antibodies having different degrees of fucosylation. | 2014-09-11 |
20140255400 | ARGININE-FREE TNFR:FC-FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF USE - Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept. | 2014-09-11 |
20140255401 | Kv1.3 Antagonists and Methods of Use - The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing. | 2014-09-11 |
20140255402 | METHOD OF TREATING LEUKEMIA IN A MAMMAL - The present invention provides a method of treating a leukemia in a mammal comprising sequentially administering to the mammal an amount of an immunotoxin and an amount of a chemotherapeutic agent effective to treat the leukemia. | 2014-09-11 |
20140255403 | ORAL COMPOSITION COMPRISING A TNF ANTAGONIST AND USE THEREOF - This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. | 2014-09-11 |
20140255404 | PULMONARY HYPERTENSION - The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension. | 2014-09-11 |
20140255405 | Removal of Monomeric Targets - The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods. | 2014-09-11 |
20140255406 | ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS). | 2014-09-11 |
20140255407 | Bispecific Molecules That Are Immunoreactive with Immune Effector Cells of a Companion Animal That Express an Activating Receptor and Cells That Express B7-H3 and Uses Thereof - The present invention relates to bispecific molecules that are immunoreactive to an activating receptor of a companion animal immune effector cell and to B7-H3, and to the use of such bispecific molecules in the treatment of cancer in companion animals. | 2014-09-11 |
20140255408 | Bispecific EGFR/C-Met Antibodies - Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. | 2014-09-11 |
20140255409 | METHOD FOR EXTRACORPOREAL ELIMINATION OF ONE OR MORE COMPONENTS FROM BLOOD - A method for extracorporeal elimination of one or more components from blood where whole blood or blood plasma is added to a blood treatment device containing an adsorbent which binds the one or more components is disclosed. The adsorbent comprises at least one matrix to which at least one ligand having specific binding affinity to said one or more component is covalently bound. The ligand comprises a glycosidically bound aglycon and at least one saccharide, preferably blood group determinant A, blood group determinant B, blood group H determinant, a P antigen, or a Pk antigen; or said ligand is an amino acid, a peptide or an antibody. Methods for treatment of transplant recipients, and to use a blood treatment device is also disclosed. | 2014-09-11 |
20140255410 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 2014-09-11 |
20140255411 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development. | 2014-09-11 |
20140255412 | Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines - The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical compositions comprising an antigenic peptide, particularly an antigenic phopho-peptide mimicking a major pathological phosphor-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease. | 2014-09-11 |
20140255413 | Combination therapy for neoplasia treatment - The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide. | 2014-09-11 |
20140255414 | DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 2014-09-11 |
20140255415 | LINGO Binding Molecules and Pharmaceutical Use Thereof - The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination. | 2014-09-11 |
20140255416 | Peptides derived from Camplobacter jejuni and their use in vaccination - Disclosed are polypeptides for | 2014-09-11 |
20140255417 | MODULATION OF MACROPHAGE ACTIVATION - The invention is generally directed to promoting M1-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-IR in a patient by assessing the in vivo or in vitro activation of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-IR on a subject being treated. | 2014-09-11 |
20140255418 | COMPOSITE BIOMARKERS FOR NON-INVASIVE SCREENING, DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER - The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG. | 2014-09-11 |
20140255419 | Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia. | 2014-09-11 |
20140255420 | Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders - The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes. | 2014-09-11 |
20140255421 | Methods and Compositions for Treating Polyps - The invention relates generally to methods and compositions for treating sinusitis, asthma, or polyps. The invention also relates to methods and compositions for treating nasal polyps. | 2014-09-11 |
20140255422 | ANTIBODIES THAT BIND TO IL-23 - The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer. | 2014-09-11 |
20140255423 | ISOLATION AND PURIFICATION OF ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY - Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 2014-09-11 |
20140255424 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS - Provided are methods of diagnosis, prognosis, and monitoring of aging using biomarkers that have been discovered to be linked to biological aging process. Methods for increasing neural cell regeneration and cognitive function are also provided. The methods are, at least in part, based on a discovery that altered expression patterns of certain biological markers are associated with biological aging processes. These markers comprise at least Eotaxin/CCL11, β2-microglobulin, MCP-1 and Haptoglobulin, increased expression of which has been shown to be associated with increase in biological aging process. | 2014-09-11 |
20140255425 | Multi-CBV Vaccine for Preventing or Treating Type I Diabetes - The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided. | 2014-09-11 |
20140255426 | WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS - In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a Wnt pathway inhibitor optionally in combination with one or more anti-viral agents. In certain embodiments, the subject is diagnosed with a chronic viral infection such as human immunodeficiency virus (HIV). | 2014-09-11 |
20140255427 | COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A NITROGEN MUSTARD - The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. | 2014-09-11 |
20140255428 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor - The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: | 2014-09-11 |
20140255429 | Methods of Treating Autoimmune Diseases with DLL4 Antagonists - The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft-versus-host disease. | 2014-09-11 |
20140255430 | METHODS AND REAGENTS FOR DETECTION AND TREATMENT OF ESOPHAGEAL METAPLASIA - The invention described herein relates to the treatment, detection, and diagnosis of various cancers, including esophageal or gastric adenocarcinoma and related metaplasias. The invention also includes a clonal population of Barrett's esophagus progenitor cells and methods of using them for the treatment, detection, and diagnosis of Barrett's esophagus. | 2014-09-11 |
20140255431 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 2014-09-11 |
20140255432 | SILVESTROL, SILVESTROL ANALOGS AND USES THEREOF - Disclosed herein are treatment methods, vaccination methods, compositions, co-therapeutic methods, combination therapeutic compositions and kits comprising silvestrol and silvestrol analogs alone or in combination with therapeutic and preventative therapies. Disclosed herein are also methods, compositions and kits that can be used to treat cancer, viral infections, to modulate the immune system or as preventative therapies. | 2014-09-11 |
20140255433 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject. | 2014-09-11 |
20140255434 | PHL P 5A DERIVATIVES HAVING REDUCED ALLERGENEITY AND RETAINED T-CELL REACTIVITY - The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies. | 2014-09-11 |
20140255435 | Vaccine - Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence | 2014-09-11 |
20140255436 | IMMUNOGENIC COMPOSITIONS USEFUL IN PROVOKING AN INTEGRATED RESPONSE TO TUMOR ANTIGENS - The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide. | 2014-09-11 |
20140255437 | TOPK PEPTIDES AND VACCINES INCLUDING THE SAME - The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers. | 2014-09-11 |
20140255438 | FUSION PROTEINS AND METHODS OF USE - Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin. | 2014-09-11 |
20140255439 | VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME - An in vitro process of preparing virus-like particles (VLPs) from recombinant papaya mosaic virus coat protein and ssRNA, which allows for large scale production of VLPs in high yields, is provided. Also provided are VLPs comprising ssRNA prepared by the in vitro process. The VLPs can be used as adjuvants and when fused to an antigen, as vaccines. The use of the VLPs for stimulation of the innate immune response is also provided. | 2014-09-11 |
20140255440 | RECOMBINANT VIRAL VECTORS AND METHODS FOR INDUCING AN IMMUNE RESPONSE TO YELLOW FEVER VIRUS - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to yellow fever virus. The invention provides recombinant viral vectors based on the non-replicating modified vaccinia virus Ankara or based on a D4R-defective vaccinia virus. When administered according to methods of the invention, the recombinant viral vectors induce a broad immune response to yellow fever virus and demonstrate an excellent safety profile. | 2014-09-11 |
20140255441 | VLPS CONTAINING LIGANDS AND METHODS RELATED THERETO - This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen. | 2014-09-11 |
20140255442 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 2014-09-11 |
20140255443 | Nucleic Acid And Amino Acid Sequences Relating To Streptococcus Pneumoniae For Diagnostics And Therapeutics - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection. | 2014-09-11 |
20140255444 | COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION - The compositions and methods of the invention described herein provide treatments against Ebola virus infection by expressing gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a recombinant viral vector. | 2014-09-11 |
20140255445 | SYNTHETIC VIRUSES AND USES THEREOF - The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response. | 2014-09-11 |
20140255446 | ACELLULAR PERTUSSIS VACCINE - Described are acellular | 2014-09-11 |
20140255447 | PRODUCTION OF AVIAN EMBRYO CELLS - The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses. | 2014-09-11 |
20140255448 | VACCINE COMPOSITION AND IMMUNIZATION METHOD - The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of | 2014-09-11 |
20140255449 | DOSAGE OF DNAK - A pharmaceutical preparation for subcutaneous injection comprising
| 2014-09-11 |
20140255450 | NOVEL COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES - The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity. | 2014-09-11 |
20140255451 | Implantable Medical Device Comprising A Macrocyclic Triene Lactone Drug And Minimal Antioxidant Stabilizer And Method Of Fabrication - The present invention relates to an oxygen-sensitive macrocyclic triene lactone that is protected by addition of an appropriate amount of an antioxidant stabilizer during fabrication of an implantable medical device comprising the macrocyclic triene lactone, wherein the amount of the antioxidant stabilizer has been reduced to a minimal, preferably, non-detect, level in the final packaged product. | 2014-09-11 |
20140255452 | METHOD AND APPARATUS FOR DIFFERENTIATING ORAL POUCH PRODUCTS - A nicotine-containing pharmaceutical product configured for insertion into the mouth of a user of that product is provided. The product can have an outer water-permeable pouch, a nicotine-containing pharmaceutical composition situated within the outer water-permeable pouch, and product identifying information relating to the nicotine-containing pharmaceutical composition. The information can be presented such that a user of the product can discern the identifying information by visually inspecting the product and thereby differentiate or identify certain nicotine-containing pharmaceutical products. The product identifying can be, for example, printed, imprinted or dyed on the outer water-permeable pouch, positioned within the outer water-permeable pouch, or attached to the outer water-permeable pouch. The product identifying information can identify product brand, a company name, a corporate logo or brand, marketing messages, product strength, active ingredient, product manufacture date, product expiration date, product flavor, product pharmaceutical release profile, weight, product code, other product differentiating markings, and combinations thereof. | 2014-09-11 |
20140255453 | HERBAL OINTMENT FOR MUSCULOSKELETAL AND JOINT-RELATED CONDITIONS - An herbal ointment. The herbal ointment may include about 40-45 weight percent of herb-infused oil, water or alcohol, or any desired combination thereof, about 30 weight percent purified water, about 10 weight percent emulsifier wax, about 5-10 weight percent menthol, about 3 weight percent dimethyl isosorbide, about 2 weight percent glycerin, about 2 weight percent hydrogenated methyl abietate, about 0.5 weight percent | 2014-09-11 |
20140255454 | METHODS OF WOUND CARE AND TREATMENT - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2014-09-11 |
20140255455 | METHODS FOR THE PRODUCTION OF A COSMETIC COMPOSITION COMPRISING LEUKOLECTIN AND USES THEREOF - The present invention relates to cosmetic compositions comprising polypeptides obtained or obtainable from Salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for improving the cosmetic appearance of skin of a mammalian animal. | 2014-09-11 |
20140255456 | Composition Containing a Cellulose Derived Capsule With a Sunscreen - A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair. | 2014-09-11 |
20140255457 | POWDERY EMULSIFYING COMPOSITION OF ALKYL POLYGLYCOSIDES, USE THEREOF FOR PREPARING COSMETIC EMULSIONS, AND METHOD FOR PREPARING SAME - A powdery composition C1 contains for 100% of the mass: 5 to 70 mass % and more particularly 10 to 50 mass % of at least one compound of formula (I): R—O-(G) | 2014-09-11 |
20140255458 | INJECTABLE BULKING COMPOSITIONS - According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable. | 2014-09-11 |
20140255459 | METHOD OF SURFACE TREATMENT OF MICRO/NANOPARTICLES BY CHEMICAL MEANS AND ITS APPLICATION TO OBTAINING A PIGMENT COMPOSITION INTENDED FOR THE FIELD OF COSMETICS, PAINT OR INKS - The subject matter of the invention is a method of surface modification of a pigment or of a composite pigment comprising at least a metal oxide, a metal complex or a derivative thereof, and the use of these pigments or composite pigments thus obtained for cosmetics, paint or inks. | 2014-09-11 |
20140255460 | NITRITE SALTS AS POISONS IN BAITS FOR OMNIVORES - The present invention relates to baits, especially baits to be used in humane methods for controlling feral omnivore populations. The invention also relates to methods of manufacturing the baits. | 2014-09-11 |